Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476
Status:
Completed
Trial end date:
2004-10-20
Target enrollment:
Participant gender:
Summary
Evaluate the percentage of subjects in remission at the end of an 8-week treatment period for
three dose groups (SPD476 1.2 g/day, 2.4 g/day or 4.8 g/day, administered once daily).